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Summary Resistance to chemotherapy is a major problem in the treatment of patients with head and neck squamous cell carcinoma
(HNSCC). Important factors involved are drug detoxification by glutathione (GSH) and reduced drug accumulation due to active transport out
of the cell by so-called 'multidrug resistance-related proteins'. We have studied a panel of eight HNSCC cell lines showing differences in
sensitivity to the anti-cancer drug cisplatin. Our previous studies indicated that the IC50 values were inversely correlated with the intracellular
accumulation of platinum (Pt). In the present study, cellular GSH levels were found not to be related to the IC50 values. The expression levels
of the enzymes glutathione S-transferase (GST) a, ,u and it, the multidrug resistance-related proteins P-glycoprotein (P-gp), multidrug
resistance-associated protein (MRP) and the lung resistance protein (LRP) were determined semiquantitatively by means of
immunocytochemistry. The levels of the GSTs, P-gp and LRP were not found to be correlated with the IC50 values of the HNSCC cell lines.
Surprisingly, however, an inverse correlation was found between MRP levels and IC50 values. The MRP expression levels were in agreement
with the results of the MRP functional assay, based on the transport of calcein across the cell membrane as performed fortwo of the cell lines.
Further studies should prove whether other pump mechanisms or DNA repair are involved in the cisplatin accumulation and the subsequent
HNSCC cell growth inhibition.
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Cisplatin shows activity in patients with advanced head and neck
squamous cell carcinoma (HNSCC). The response of these
tumours differs between patients, but a good initial response is
generally seen upon cisplatin chemotherapy in 20-50% of the
cases (Vokes et al, 1993). Nevertheless, treatment does not lead to
an increased survival as a consequence of a lack ofresponse or its
short duration.
Various mechanisms have been proposed to explain resistance
to cisplatin (Hayes andWolf, 1990). The role ofglutathione (GSH)
in cisplatin resistance seems to be important as cells with in vitro
acquired resistance often show elevated levels of GSH compared
with the parental cells (Meijer et al, 1992; Goto et al, 1995).
Glutathione S-transferases (GST) are enzymes that catalyse the
conjugation of cisplatin to GSH. The cisplatin-GSH complex has
been proposed to be ejected from the cell in an ATP-dependent
fashion by the glutathione S-conjugate (GS-X) export pump
(Ishikawa and Ali-Osman, 1993; Goto et al, 1995).
ATP-dependent transport systems, referred to as pumps, are
proposed to be responsible for resistance to multiple drugs, i.e.
multidrug resistance (MDR) (Biedler, 1992). Two important MDR-
associated membrane-bound proteins are P-glycoprotein (P-gp),
encoded by theMDR] gene, and the multidrug resistance-associated
protein (MRP) (Broxterman et al, 1995; Nooter et al, 1995). P-gp
and MRP actively transport a wide range of substrates across
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membranes into vesicles and out from the cell. A number of
substrates are transportedby MRP afterconjugation to GSH (Muller
et al, 1994). Another MDR-associated protein, recently discovered,
is the lung resistance protein (LRP), possibly mediating intracellular
transport (Scheper et al, 1993; Scheffer et al, 1995). Although
cisplatin is not known to induce MDR itself, MDR-induced cells
can become cross-resistant to cisplatin (Loe et al, 1996). The
possible involvement of MDR in the response to platinum (Pt)-
based treatments has been reported in apanel of61 human cell lines
of eight different cancer types (Izquierdo et al, 1996a) and in
patients with ovarian cancer (Izquierdo et al, 1995). HNSCC was
not included in these studies, although otherstudies have shown that
HNSCC cells can express P-gp (Kelley etal, 1993), MRP (Nooteret
al, 1995), as well as LRP (Izquierdo et al, 1996b).
Using a panel ofeight HNSCC cell lines that differ in cisplatin
sensitivity, we were able to show an inverse correlation between
IC50 values and Pt accumulation (Welters et al, 1997). To investi-
gate the underlying mechanism of differences in cisplatin sensi-
tivity and Pt accumulation, we presently report on the GSH levels
and the expression levels ofthe GST isoenzymes as well as ofthe




Human HNSCC cell lines UM-SCC-IIB, UM-SCC-14C, UM-
SCC-22A, UM-SCC-22B and UM-SCC-35 were described by
Carey et al (1990). These cell lines were established from fresh
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tumour biopsies. The same holds for cell lines 92VU040T and
93VU120T (Hermsen et al, 1996). VU-SCC-OE was established
in our laboratory from a HNSCC xenograft (Welters et al, 1997).
Cells were routinely cultured in Dulbecco's modified Eagle
medium (Life Technologies, Gibco BRL, Breda, The Netherlands)
supplemented with 5% heat-inactivated fetal calf serum (Flow,
Irvine, UK), 50 U ml' penicillin and 50 g ml' streptomycin
(Life Technologies).
Cisplatin treatment
HNSCC cells at subconfluency were treated with cisplatin for
72 h, washed twice with phosphate-buffered saline (PBS) and
harvested by use oftrypsin. The IC50 data ofthe HNSCC cells, i.e.
the concentration of the drug causing 50% of growth inhibition
compared with that ofuntreated control cells, have been published
before (Welters et al, 1997) and were determined with the
sulphorhodamine B (SRB) assay (Braakhuis et al, 1993).
GSH content in cultured human HNSCC cells
GSH was measured in untreated and cisplatin-treated HNSCC
cells by high-performance liquid chromatography (HPLC)
combined with precolumn derivatization with orthophthaldehyde
and fluorometric detection (Neuschwander-Tetri and Roll, 1989).
GSH levels per cell line were measured in two or three indepen-
dent samples ofcells cultured at subconfluency.
Immunocytochemical staining of GST isoenzymes
Expression ofthe GST isoenzymes cc, ,u and it was analysed using
the immunoperoxidase staining method described by Bongers et al
(1995). HNSCC cells were deposited on glass slides with a
cytospin centrifuge, fixed with methanol for 10 min and washed
with PBS. A 30-min preincubation was performed with 2% normal
swine serum (Dako, Copenhagen, Denmark) diluted in PBS
containing 1% bovine serum albumin (BSA; Sigma, St Louis,
MO, USA), followed by incubation with rabbit antisera directed
Table 1 Parameters determining cisplatin sensitivity in cultured HNSCC
cells
Cell line IC50valuea Pt accumulationb GSH levelsc
UM-SCC-35 0.9 ± 0.8 159 ± 93 10.2 ± 1.8
UM-SCC-22B 1.2 ± 0.3 149 + 34 5.0 ± 2.3
UM-SCC-22A 1.3 ± 0.3 109 ± 9 6.3 + 2.6
92VU040T 2.0±0.5 67±7 11.2+3.1
UM-SCC-11B 2.2 ± 0.6 126 ± 9 7.5 ± 1.1
VU-SCC-OE 2.3 + 0.9 566 + 317 7.1 ± 0.7
UM-SCC-14C 2.7 +0.7 81 ± 10 2.0 ± 1.2
93VU120T 2.8±1.0 89±10 6.1 ±0.7
aThe sensitivity to cisplatin was determined by a cell proliferation (SRB)
assay. The IC50 value, the concentration of the drug causing 50% growth
inhibition after a 72-h treatment, is given in gM cisplatin. These results were
obtained in a previous study and were reported to be significantly correlated
with Pt accumulation data when those of cell line OE were omitted (Welters
et al, 1997). bThe total amount of Pt accumulated in the cells (expressed as
pmol Pt per 106 cells), after treatment with 10gM of cisplatin for 72 h, was
determined with AAS in a previous study (Welters et al, 1997). cGlutathione
(GSH) levels (fmol per cell) were determined by HPLC according to
Neuschwander-Tetri et al (1989)
against GST-oc, -jt and -x respectively (antisera diluted 1:1 in
PBS/1% BSA; NovoCastra, Newcastle upon Tyne, UK). The
preparations were washed three times with PBS (5 min each), and
treated for 10 min with 0.006% hydrogen peroxide in methanol to
inhibit endogenous peroxidase activity, followed by three wash-
ings with PBS. The slides were then incubated for 30 min with
swine anti-rabbit biotin conjugate (diluted 1:500 in PBS/1% BSA;
Dako) and washed again three times with PBS. After a further
incubation for 60 min with avidin-biotin complex (Vectastain
ABC-kit, Vector Laboratories, Burlingame, CA, USA), and three
wash steps, antibody binding was visualized by incubation with
4 mg (v/v) of 3,3'-diaminobenzidine tetrahydrochloride (Sigma)
and 0.02% (v/v) hydrogen peroxide in PBS for 3-5 min. The slides
were rinsed with tap water, counterstained with haematoxylin
(Merck, Darmstadt, Germany), and finally mounted with Kaiser's
glycerin gelatin (Merck). As a negative control, slides were incu-
bated as described above except that the primary antibody was
replaced by PBS/1% BSA or mouse IgG antibody. In two indepen-
dent experiments, all cell lines were stained simultaneously with
the various antibodies.
Immunocytochemical staining of P-gp, MRP and LRP
The HNSCC cells were cultured until subconfluency and
harvested onto cytocentrifuge slides, which were stored at -20°C
until analysis. Immunocytochemistry was performed as described
by Izquierdo et al (1996b). In short, after thawing the cytocen-
trifuge preparations were acetone-fixed (10 min) before preincu-
bation with 2% normal rabbit serum for 15 min (Dako). Then,
slides were incubated for 60 min at room temperature with one of
the following monoclonal antibodies (MAb): mouse MAb JSB-1
(1:100 of 10 ,ug ml-') against P-gp, mouse MAb MRP-m6 (1:25 of
1 ug ml-') and rat MAb MRP-rl (1:1500 of 1 jg ml-') against
MRP, rat MAb LRP-56 (1:500 of 0.5 ,ug ml-') and LMR-5 (1:500
of 0.5,g ml-') both directed against LRP. These antibodies are
available from Sanbio, Uden, The Netherlands. After washing
with PBS for 15 min, the slides were incubated for 60 min with
rabbit anti-mouse biotin (1:150; Zymed Laboratories, San
Francisco, CA, USA) or rabbit anti-rat biotin (1:100) conjugate
(Dako), washed and incubated with streptavidin coupled to horse-
radish peroxidase (1:500; Zymed Laboratories) for 60 min. All
dilutions were in PBS with 1% BSA. The washed cells were
finally stained with amino-ethyl-carbazole (ICN Biochemicals,
Aurora, OH, USA) for 5 min and counterstained with haema-
toxylin (Merck). As a negative control, irrelevant IgG or PBS was
used instead of the primary antibody. Positive controls for the
expression of each of the proteins were KB-8-5 cells for P-gp
(Izquierdo et al, 1995), GLC4/ADR cells for MRP and SW-
1573/2R120 cells for LRP (Scheper et al, 1993; Flens et al, 1994;
Broxterman et al, 1996). Immunohistochemical staining ofthe cell
lines was performed in two independent experiments (I and II) and
all slides ofeach experiment were stained simultaneously.
Evaluation of immunocytochemical staining
The evaluation was performed using light microscopy on coded
slides. Scoring of each immunocytochemical experiment was
performed blindly and independently by three observers. The
number ofcells that stained very strong (+ + +), strong (+ +), inter-
mediate (+) or not (-) was expressed as a percentage of the total
number of cells investigated. The semiquantitative staining index
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Table 2 Correlation between IC50 values of the HNSCC cell lines and the
expression levels of GST and MDR-related proteins
Marker Antibody Experiment I ExperimentII
designation
r-value P-value r-value P-value
GST-a GSTalpha -0.02 0.95 -0.05 0.89
GST-p GSTmuM2 0.71 0.06 0.41 0.31
GST-s GSTpi 0.57 0.13 0.57 0.12
P-gp JSB-1 -0.50 0.19 -0.52 0.17
MRP MRP-m6 -0.79 0.04 -0.71 0.05
MRP-rl -0.83 0.03 -0.83 0.03
LRP LRP-56 -0.45 0.23 -0.47 0.22
LMR-5 -0.60 0.12 -0.45 0.29
The relations between the IC50 values and the expression levels of the
various markers, which were recognized and visualized by antibodies, were
determined in two independent experiments. The Spearman's rank
correlation coefficients (r-values) and significancies (P-values) are given.
ofeach group was calculated as the product ofthis percentage and
the staining intensity. The latter was estimated on a scale of 1 (+)
to 3 (+ + +). The variation in scores between the three observers,
expressed as a coefficient of variation, i.e. the s.d. as a percentage
ofthe mean, was always less than 30%. Intraobserver variation of
scoring was tested and was proved to be less than 20%.
Functional MRP test
The HNSCC cell lines UM-SCC-14C that showed a low sensi-
tivity to cisplatin and UM-SCC-35, the most sensitive cell line of
our panel, were analysed in two independent experiments for the
presence of functional MRP as described by Feller et al (1995).
Briefly, about 0.5 x 106 cells were allowed to take up calcein-
acetoxymethylester (calcein-AM) by incubation in 0.5 ,UM of this
dye for 10 min at 37°C. They were washed and subsequently incu-
bated in fresh medium with or without the MRP inhibitor
probenecid (1.0 mm, Sigma) for 0, 10 or 60 min. The efflux was
stopped by centrifugation of the cells and addition of ice-cold
culture medium. In this assay, the non-fluorescent dye calcein-AM
is converted by intracellular esterases to the fluorescent calcein.
The calcein can be exported by active MRP, which can be
prevented by the use of the MRP inhibitor. The intracellular
calcein is then analysed using FACScan flow cytometry (Becton
Dickinson Medical Systems, Sharon, MA, USA). The human
small-cell lung cancer cell line GLC4, which is MRP negative,
and its MRP-overexpressing subline GLC4/ADR were used as
controls (Feller et al, 1995).
Statistical analysis
Correlations between the various cellular parameters and the
IC50 values of the cultured HNSCC cells were determined by
Spearman's rank correlation test; the correlation coefficients
(r-values) and the P-values (two-sided) were calculated. Only
correlations with P-values of0.05 or below were considered to be
significant.
RESULTS
The efficacy of cisplatin treatment in a panel of eight human














Figure 1 The relationship between the sensitivity to cisplatin, expressed as
IC50 value, and the semiquantitative staining index of MRP using either
antibody MRP-m6 (@; solid line) or MRP-rl (A; dashed line) as determined
in the two independent experiments I (A) and 11 (B)
protein levels. As previously published, the IC50 values varied
about three-fold between the cell lines and showed a significant
inverse correlation with the Pt accumulation in these cells when
data of cell line OE (derived from a previously irradiated patient)
were omitted (Table 1; Welters et al, 1997).
GSH levels in untreated and cisplatin-treated cells
The total levels of GSH in the eight HNSCC cell lines varied
between 2.0 fmol percell forUM-SCC-14C and 11.2 fmol percell
for 92VU040T (Table 1). No correlation was found with the IC50
values or the cellular Pt content. The GSH level in the VU-SCC-
OE cells appeared to be within the range ofthe othercell lines and
could, therefore, not explain the moderate sensitivity of this cell
line and its high Pt content. To study possible induction ofGSH by
cisplatin treatment, cell lines UM-SCC-14C, VU-SCC-OE and
UM-SCC-35, showing differences in IC50 values, were. treated
with 0.1 and 1.0 gM cisplatin during 5 and 24 h. In these treated
cells, a small increase ofGSH levels was foundcompared with the
untreated cells (data not shown). However, this induction ofGSH
was slightly different among the cell lines. Therefore, these differ-
ences in cisplatin-induced GSH levels cannot be held responsible
for the variation in IC50 values found for these cell lines.
Expression of the GST isoenzymes
In all HNSCC cell lines, the presence ofthe three isoforms GST-a,
GST-,u and GST-it could be demonstrated by immunocytochemical
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Table 3 Activity of MRP protein
Cell line Duration of calcein efflux
t= 10 mina t= 60 minb
UM-SCC-35 1.54 ± 0.05 1.47+ 0.21
UM-SCC-14C 1.02 + 0.03 1.22 ± 0.15
GLC4 0.94 1.10 ± 0.03
GLC4/ADR 2.0 3.05 + 0.39
The effect of the MRP inhibitor (1.0 mm probenecid) is expressed as the ratio
of calcein accumulation in the presence of this modulator divided by that in
the absence of probenecid, measured after a duration of al0 min or b60 min of
calcein efflux. GLC4 was included as negative and GLC4/ADR as positive
control cells. Experiments were performed in duplicate, except for the 10 min
incubation experiment of GLC4 and GLC4/ADR.
staining. Over 90% ofthe cells ofeach line were positive for GST-
it. The staining percentages forthe other two GST isoenzymes were
lower and varied considerably between the cell lines. For GST-at
the percentage of positively stained cells varied between 15% and
100%, whereas for GST-,u it varied from 3% to 100%. The calcu-
lated staining indices (see Material and methods) differed between
the cell lines and between the three isoforms of GST, but none of
these correlated with the IC50 values (Table 2), neither with the Pt
accumulation in these cells after 72 h of exposure to cisplatin nor
with the GSH levels determined in the untreated cells.
Expression of MDR-related proteins
The expression level of the MDR protein P-gp, visualized by use
of antibody JSB-1, was expressed in all HNSCC cell lines tested,
with staining index ranging from 128 (93VU120T) to 262 (UM-
SCC-35). The levels of MRP, measured with specific mouse and
rat antibodies, were also different for the various HNSCC lines.
The UM-SCC-14C cells appeared to be stained very weakly or not
at all, indicating that MRP levels were relatively low. The data
obtained with the mouse and rat anti-MRP antibodies were corre-
lated significantly, resulting in a correlation coefficient (r-value)
of0.72 (P = 0.05) in the first and r = 0.80 (P = 0.04) in the second
experiment. The staining index ofLRP-56, a measure of the pres-
ence of LRP, ranged from 107 for UM-SCC-14C cells to 202 for
cell line UM-SCC-35. With the LMR-5 antibody, which also
recognizes LRP, similar variations in staining level were observed.
The results obtained with these two antibodies recognizing LRP
did significantly correlate in the two experiments (r = 0.63,
P = 0.02 and r = 0.72, P = 0.05).
To find out whether the levels ofthese three membrane proteins
have an effect on the sensitivity of the cells to cisplatin, the rela-
tionships between these levels and the IC50 values were deter-
mined. A significant inverse correlation was found in the first
experiment between the IC50 values and MRP, as indicated by the
staining index of MRP-m6 (r = -0.79, P = 0.04) and of MRP-rl
(r = -0.83, P = 0.03) (see Fig. IA and Table 2). The second exper-
iment (Fig IB) confirmed this finding, showing a significant corre-
lation of IC50 values with the MRP-m6 staining index (r = -0.71,
P = 0.05) as well as with the MRP-rl staining index (r = -0.83,
P = 0.03). No correlation was found between the IC50 values and
the P-gp or the LRP levels (Table 2).
Whether or not the total amount of Pt accumulated in the
HNSCC cells (with the exception of VU-SCC-OE) is correlated
with the expression levels of MRP as visualized with antibody
MRP-m6 is not quite clear. In the first experiment, the correlation
was found not to be significant (r = 0.68, P = 0.09), but in the
second experiment it was significant (r= 0.89, P = 0.03). The same
holds true for the results obtained with the other MRP-recognizing
antibody, showing a significant correlation between Pt accumula-
tion levels and MRP-rl staining results, in experiment I (r = 0.77,
P = 0.05) and no significance in experiment II (r = 0.61, P = 0.13).
Functional MRP test
Cell lines UM-SCC-14C and UM-SCC-35, which differed signifi-
cantly in MRP expression, were used to determine if the estab-
lished differences in the levels of MRP were indicative for
differences in the MRP activity in the cells. The results of the
assay are given in Table 3. The UM-SCC-14C cells showed hardly
any activity ofthe MRP pump, whereas the cells ofline UM-SCC-
35 appeared to have functional MRP after 10-min and 60-min
treatments determined with the MRP inhibitor probenecid. This is
in agreement with the immunocytochemical staining results, in
which the presence of MRP could not be demonstrated in UM-
SCC-14C cells whereas a relatively high expression was observed
in UM-SCC-35.
DISCUSSION
Our data indicate a minor role for GSH as a determining factor of
the differences in sensitivity to cisplatin of the presently studied
HNSCC cell lines. An inverse correlation between the GSH levels
and cisplatin sensitivity has been reported for cell lines of various
tumour types, thereby partly explaining the resistance found
(Mistry et al, 1991; Meijer et al, 1992). It should be noted that we
studied cell lines that were not treated in vitro to obtain acquired
resistance. Because Yellin et al (1994) reported that the GSH
levels in HNSCC cells can be up-regulated during cisplatin treat-
ment, the GSH levels were also determined in the cell lines UM-
SCC-14C, UM-SCC-35 and VU-SCC-OE after incubation with
cisplatin during various time periods. As a result, only small
increases in GSH levels occurred, but this did not lead to correla-
tions with the IC50 values.
In the detoxification system GSH/GST, GSTs catalyse the
binding of electrophilic components to GSH. Three isoforms of
GST can be distinguished in humans namely ic (acidic), g (neutral)
and x (basic). Expression of GSTs and MDR-related proteins was
studied by immunocytochemistry. This was known to be a reliable
method because for these proteins a correlation was found with the
outcome of Western blots, immunoprecipitation analyses and the
determination ofthe corresponding mRNA levels (Flens et al, 1994;
Nooter et al, 1995; Scheffer et al, 1995). Comparison of the GST
staining indices of our eight HNSCC lines with the IC50 values of
these lines revealed no correlation (see Table 2), which is in agree-
ment with the results ofYellin and colleagues (1994) for a panel of
14 HNSCC lines. It cannot be excluded that the other factors in the
GSH-associated detoxification system play a role in cisplatin sensi-
tivity; this includes the enzymes glutathione peroxidase, glutathione
synthetase, glutathione reductase and dipeptide gamma-glutamyl-
cysteine (Kramer et al, 1988; Kurokawa et al, 1995).
The importance of the MDR proteins in the efficacy of Pt-
containing chemotherapy has recently been reported for leukaemia
cells and colon carcinomas (Ishikawa et al, 1994; 1996). In the
present study, no significant correlation was found between P-gp
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expression levels and the IC50 values, suggesting no direct involve-
ment ofP-gp in the in vitro response ofHNSCC cells to cisplatin. A
significant, but inverse correlation was found between MRP and
the IC50 values (Table 2). MRP was detected on the membranes of
HNSCC cells, as well as inside these cells, with the two antibodies
MRP-m6 and MRP-rl. The staining results obtained with MRP-m6
were significantly correlated with those ofMRP-rl, which is in line
with results reported by Izquierdo et al (1996a). It should be noted
that these antibodies do not cross-react with human MDR1 and
MDR3 P-gps (Flens et al, 1994). A high expression of MRP is
usually determined in cell lines with acquired resistance (Muller et
al, 1994; Brock et al, 1995). It is thought that MRP is a GS-X pump
(Muller et al, 1994; Loe et al, 1996; O'Brien and Tew, 1996), which
is present on vesicles and/or the plasma membrane (Nooter et al,
1995). The unexpected finding in our panel of HNSCC that the
correlation ofMRP with the IC50 data was inverse (Fig 1), and thus
positive with sensitivity, and that high cellular Pt levels were asso-
ciated with high MRP expression levels cannot be attributed to less
active MRP because we provided evidence that the MRP was
indeed active as determined by the functional MRP assay (see
Table 3). These data implicate that in HNSCC cells the GS-X pump
activity, i.e. transporting GSH-conjugated cisplatin out of cells,
may not be the major function of MRP. This is in agreement with
the results of De Vries et al, (1995). A possible explanation for the
unexpected relation of higher sensitivity in the presence of more
MRP may be that endogenous metabolites conjugated to GSH are
extruded from the cell, whereas cisplatin is counter-transported.
Another hypothesis is the regulation ofendogenous (ion) channels,
and possibly other transporters, by MRP as described by Loe and
colleagues (1996), which can lead to an increase of the influx of
cisplatin into the cells and eventually into the nucleus. As a conse-
quence, the levels ofDNA-bound Pt will increase. The involvement
ofother as yet undefined transport mechanisms in the sensitivity to
cisplatin ofthe HNSCC lines under study also cannot be ruled out.
Possible candidates for alternative pumps are the human canalicular
multispecific organic anion transporter (cMOAT), also designed as
MRP2. which has been described to be overexpressed in the
cisplatin-resistant human head and neck cancer KB cell line
(Taniguchi et al, 1996) and the SQM1 protein, which is present at
reduced levels in HNSCC resistant to methotrexate and cisplatin
(Bernal et al, 1990).
High expression of the non-P-gp LRP protein in acute myeloid
leukaemia and ovarian carcinoma has been associated with a poor
response to chemotherapy, such as cisplatin treatment (Izquierdo
et al, 1995; Scheffer et al, 1995). In our HNSCC cell lines LRP
was detectable, which is in agreement with the earlier published
finding that this protein is present in epithelial cells (Scheffer et al,
1995) and head and neck tumours (Izquierdo et al, 1996b). No
correlation was found between LRP expression levels and the IC5
values (Table 2), or with the Pt accumulation data. These results
are in contrast with those found by Izquierdo and colleagues
(1996a), who showed a predictive value of LRP for in vitro sensi-
tivity to several types of drugs, among which also cisplatin, in a
number of cancer types. Their study, however, did not include
HNSCC. Our results in eight HNSCC cell lines indicate that pump
mechanisms other than LRP control the response of this cancer
type to cisplatin. The importance of DNA damage recognition
proteins in DNA repair and the nucleotide excision repair system
in repairing cisplatin-DNA damage has been reviewed by Hill
(1996). It is clear also that other unknown factors may contribute
to the differences in sensitivity to cisplatin in our HNSCC cell
lines. In addition, it is obvious that intrinsic sensitivity to drugs is a
very complex phenomenon that needs further investigation.
In conclusion, an inverse correlation was found between the
IC50 values of HNSCC cell lines, obtained after 72 h of cisplatin
treatment, and their expression level of the MDR-associated
membrane-bound protein MRP. In addition, the indications for a
positive relation between Pt accumulation and MRP expression
levels suggest that MRP plays a role in transport of cisplatin into
or inside the HNSCC cells.
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